EU approves Sanofi's second MS drug Lemtrada

09/17/2013 | Reuters

Sanofi obtained approval from the European Commission to market its injectable drug Lemtrada, or alemtuzumab, for treatment of multiple sclerosis. Lemtrada will join Sanofi's other MS drug, Aubagio, which was cleared in Europe in the past month. Sanofi plans to begin selling both treatments in the European Union soon.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC